PET显像衍生预后因素用于伴内脏转移的前列腺癌患者接受[177Lu]Lu-PSMA放射配体治疗
本研究回顾性纳入320例接受[177Lu]Lu-PSMA RPT的mCRPC患者,其中65例伴内脏转移。全体队列中位OS为15个月,伴内脏转移者为10个月、无内脏转移者为16个月。在内脏转移亚组中,PSMA-TV、miPSMA表达评分和转移模式为独立预后因素,具备两个及以上风险因素者OS仅4个月。
要点
- 伴内脏转移的mCRPC患者接受[177Lu]Lu-PSMA RPT后中位OS为10个月,显著低于无内脏转移者的16个月。
- 内脏转移亚组中,PSMA-TV、miPSMA表达评分和转移模式是独立预后因素。
- 具备两个及以上风险因素者中位OS为4个月,而最多一个风险因素者为15个月。
核心结论
- 内脏转移是接受[177Lu]Lu-PSMA RPT的mCRPC患者的主要风险因素。
- RPT前PSMA-PET衍生参数可区分内脏转移患者中的高风险与低风险亚组,有助于治疗分层。
研究设计与样本
- 单中心回顾性真实世界研究,纳入320例接受[177Lu]Lu-PSMA RPT的mCRPC男性患者,共1077个治疗周期(每例1–12周期)。
- 评估基线特征(年龄、PSA水平、Gleason评分、转移部位、既往治疗)作为全体队列的潜在预后因素。
- 在内脏转移亚组(65例)中分析PET衍生参数:全身PSMA阳性肿瘤体积(PSMA-TV)、SUVmax、SUVmean、miPSMA表达评分及内脏转移模式。
主要发现
- 全体队列估计中位总生存期(OS)为15个月。
- 多因素Cox回归中,内脏转移、Gleason评分和PSA水平是全体队列的显著负性预后基线因素。
- 伴内脏转移患者估计中位OS为10个月,显著低于无内脏转移者的16个月。
- 内脏转移亚组多因素Cox回归中,PSMA-TV、miPSMA表达评分和转移模式被确定为独立预后因素。
- 具备两个及以上风险因素者OS为4个月,显著差于最多一个风险因素者的15个月。
关键数值与推荐
- 全体队列估计中位OS为15个月;伴内脏转移者中位OS为10个月,无内脏转移者为16个月。
- 内脏转移亚组中,PSMA-TV、miPSMA表达评分和转移模式为独立预后因素。
- 具备两个及以上风险因素者中位OS为4个月,最多一个风险因素者为15个月。
临床怎么用
- 对伴内脏转移的mCRPC患者,RPT前可利用PSMA-PET衍生参数(PSMA-TV、miPSMA表达评分、转移模式)进行风险分层。
- 具备两个及以上风险因素的内脏转移患者OS仅4个月,可考虑更积极的治疗策略或临床试验。
局限性
- 本研究为单中心回顾性真实世界研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Visceral metastases are a significant risk factor and may be the most critical determinant of outcome in patients with metastatic castration-resistant prostate cancer (mCRPC) undergoing [¹⁷⁷Lu]Lu-PSMA RPT. In this monocentric real-world study, we evaluated baseline parameters derived from PET scans prior to RPT in order to identify potential prognostic factors in mCRPC patients with visceral metastases. MATERIALS AND METHODS: This retrospective study included 320 men with mCRPC treated with in total 1077 cycles of [177Lu]Lu-PSMA RPT (1–12 cycles/patient). Baseline characteristics, including age, PSA level, Gleason score, metastatic sites, and prior treatments, were evaluated as potential prognostic factors in the overall cohort. 65 patients were diagnosed with visceral metastases. In this subgroup, we analyzed the PET-derived parameters whole body PSMA-positive tumor volume (PSMA-TV), SUVmax, SUVmean, miPSMA expression score and the metastatic pattern of visceral metastases. RESULTS: The estimated median overall survival (OS) for the entire cohort was 15 months. Presence of visceral metastases, Gleason score, and PSA level were significant negative prognostic baseline factors for the entire cohort in the multivariate Cox regression score. The estimated median OS for patients with visceral metastases was 10 months, which was significantly lower than the 16 months observed for patients without visceral metastases. PSMA-TV, miPSMA expression score, and the metastatic pattern were identified as independent prognostic factors in multivariate Cox regression analysis. Patients exhibiting two risk factors or more demonstrated a significantly poorer OS of 4 months compared to patients with a maximum of one risk factor, who showed an OS of 15 months. CONCLUSION: This study confirmed that visceral metastases represent a major risk factor in patients with mCRPC undergoing [177Lu]Lu-PSMA RPT. Moreover, PSMA-PET-derived parameters assessed prior to RPT enabled the distinction between high-risk and low-risk subgroups among patients with visceral metastases. These prognostic factors may therefore contribute to improved therapy stratification in mCRPC patients with visceral metastases undergoing [177Lu]Lu-PSMA RPT.
引用
- Späth MS, Dittmann H, Spallek R, et al. PET-imaging derived prognostic factors for prostate cancer patients with visceral metastases receiving [177Lu]Lu-PSMA radiopharmaceutical therapy (RPT). Eur J Nucl Med Mol Imaging. 2026. PMID: 41528461. doi:10.1007/s00259-025-07712-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。